Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Abiomed Inc (ABMD) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Abiomed Inc (ABMD) lobbying for?
Summary of the lobbying data:
Abiomed Inc has submitted 10 lobbying contracts and have hired Ml Strategies, Bgr Government Affairs, Inc, Abiomed, Llc, Akin Gump Strauss Hauer & Feld as their lobbying firms. They lobbied on general issues related to Taxation/Internal Revenue Code, Medicare/Medicaid, and Health Issues. The specific issues they lobbied on include issues related to Medicare reimbursement, FDA user fee reauthorization and the use of real world data, the Consolidated Appropriations Act, FDA regulatory policy, federal medical device policy and regulatory issues, Medicare program reimbursement issues, heart recovery as the standard of care and increased diversity CV clinical trials, FDA breakthrough medical device issues, IPPS Regulation, Medicare coverage reform, and Health Equity. They lobbied the Senate, Department of Health & Human Services (HHS), Centers For Medicare and Medicaid Services (CMS), and the House of Representatives.
One could infer that Abiomed Inc is lobbying on these issues in order to affect policy change in their favor. Specifically, they are looking to increase Medicare reimbursement rates for their medical devices, as well as ensure that FDA regulations and policies are supportive of their business interests. They are also interested in improving clinical trial diversity and standardizing heart recovery care. Additionally, they are working to ensure their supply chain for medical products is optimized and to prevent unfavorable Medicare coverage reforms that could impact their business.
